BiotechTube
Home/Pipeline/Vaccine Immune Response (SARS-CoV-2)

Vaccine Immune Response (SARS-CoV-2)

Infectious Disease

PreclinicalActive

Key Facts

Indication
Infectious Disease
Phase
Preclinical
Status
Active
Company
CellChorus

About CellChorus

CellChorus is a private, early-stage biotech company founded in 2019 that has developed a unique AI-powered platform for dynamic single-cell functional analysis. Its core technology, TIMING™, visualizes and quantifies the behavior of thousands of individual cells in parallel, providing insights into cell therapy potency, antibody function, and immune response that are missed by conventional bulk or static single-cell methods. The company operates primarily as a technology platform and services provider, supporting pharmaceutical and biotech clients in preclinical research, candidate selection, and manufacturing consistency. CellChorus is positioned to address critical bottlenecks in immunotherapy development by delivering high-content, single-cell kinetic data.

View full company profile

Therapeutic Areas

OncologyInfectious Disease

Other Infectious Disease Drugs

DrugCompanyPhase
Vaccine PlatformBiolingusResearch
Pipeline AntibioticsBioQ PharmaUnknown
Antivirals PlatformQubit PharmaceuticalsDiscovery
Antibiotic Development ProgramAF ChemPharmPre-clinical
Prophylactic Vaccine DevelopmentImmuneSpecService
Optimized VHH vs. SARS-CoV-2Ordaos BioPre-clinical
Undisclosed Vaccine Program(s)Brazos BiomedicalPre-clinical
Undisclosed Asset 1Uvax BioResearch
Undisclosed Asset 2Uvax BioResearch
Undisclosed Asset 3Uvax BioResearch
XmAb®662XencorPreclinical
C1-based Therapeutic AntigenDyadicPhase I